• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,328.19 -516.33
( -0.66%)
Global Indices
Nasdaq
49,619.91 1.93
(0.00%)
Dow Jones
7,417.79 59.68
(0.81%)
Hang Seng
62,681.30 -152.54
(-0.24%)
Nikkei 225
10,228.01 -48.94
(-0.48%)
Forex
USD-INR
94.38 -0.30
(-0.31%)
EUR-INR
110.93 -0.26
(-0.23%)
GBP-INR
128.32 -0.39
(-0.30%)
JPY-INR
0.60 0.00
(-0.28%)

EQUITY - MARKET SCREENER

Saakshi Medtech & Panels Ltd
Industry :  Diversified - Medium / Small
BSE Code
ISIN Demat
Book Value()
91668
INE0PSK01027
55.5305279
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SAAKSHI
100.77
475.03
EPS(TTM)
Face Value()
Div & Yield %
2.67
10
0
 

balaxi pharmaceuticals ltd
Hyundai Motor India Q3 PAT rises 6% YoY to Rs 1,234 crore
Feb 02,2026
Total revenue from operations grew 7.96% year-on-year (YoY) to Rs 17,973.49 crore during the quarter.

Profit before tax in Q3 FY26 stood at Rs 1,666.03 crore, up 6.61% from Rs 1,562.73 crore recorded in Q3 FY25.

During the quarter, EBITDA rose 7.61% YoY to Rs 2,018.30 crore from Rs 1,875.50 crore in Q3 FY25, while the EBITDA margin declined marginally to 11.2% from 11.3% in the year-ago quarter.

On a nine-month basis, the company reported a 3.72% increase in consolidated net profit to Rs 4,175.89 crore in 9M FY26, compared with Rs 4,025.86 crore in 9M FY25. Revenue from operations rose 1.16% YoY to Rs 51,847.18 crore in 9M FY26.

Tarun Garg, managing director & chief executive officer, said, “The third-quarter performance underscores our resilience and strong execution of “Quality of Growth” strategy, marked by healthy growth in volumes, revenue and profitability. Notably on a year-to-date basis, EBITDA margins expanded to 12.8% as against 12.5% last year, supported by our efforts towards improving sales mix and prudent cost control measures. As we move ahead, the robust January’26 sales number gives us great momentum towards a healthy 2026.”

Hyundai Motor India manufactures and sells passenger cars, along with vehicle parts and accessories.

The counter rose 0.60% to settle at Rs 2,196.50 on the BSE.